Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Mar;8(3):e130-e137.
doi: 10.1016/S2352-3018(20)30307-6.

Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial

Jessica E Haberer  1 , Elizabeth A Bukusi  2 , Nelly R Mugo  3 , Maria Pyra  4 , Catherine Kiptinness  5 , Kevin Oware  6 , Lindsey E Garrison  7 , Katherine K Thomas  8 , Nicholas Musinguzi  9 , Susan Morrison  8 , Peter L Anderson  10 , Kenneth Ngure  11 , Jared M Baeten  12 ; MPYA Study Team
Collaborators, Affiliations
Randomized Controlled Trial

Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial

Jessica E Haberer et al. Lancet HIV. 2021 Mar.

Abstract

Background: Pre-exposure prophylaxis (PrEP) is highly effective for preventing HIV acquisition. However, adherence among young women (aged 18-24 years) has been challenging. SMS reminders have been shown to improve adherence to antiretroviral therapy in some contexts, including in combination with real-time adherence monitoring. We aimed to determine the effect of SMS reminders on PrEP adherence among young women in Kenya over a 2-year period.

Methods: The monitoring PrEP among young adult women (MPYA) study was an open label randomised controlled trial involving young adult women at high risk of HIV in Thika and Kisumu, Kenya. Participants were recruited from colleges, vocational institutions, informal settlements, and community-based organisations supporting young women. Women had to be aged 18-24 years and at high risk of HIV acquisition (defined as a VOICE risk score of 5 or higher, or being in a serodiscordant relationship). Study staff randomly assigned participants (1:1) to receive either SMS reminders (SMS reminder group) or no reminders (no SMS reminder group). Study group assignment was known to trial staff but masked to investigators. Reminders were initially sent daily and participants could switch to as-needed reminders (ie, sent only if they missed opening the monitor as expected) after 1 month. Study visits occurred at 1 month, 3 months, and then quarterly (ie, every 3 months). The primary outcome was PrEP adherence over 24 months measured with a real-time electronic monitor and assessed by negative binomial models adjusted for the study site and quarter among participants who collected PrEP. This trial is registered with ClinicalTrials.gov, NCT02915367.

Findings: Of 642 women initially approached, 348 eligible women were enrolled between Dec 21, 2016, and Feb 5, 2018. Participants were randomly assigned to either the SMS reminder group (n=173) or the no SMS reminder group (n=175). The median age was 21 years (IQR 19-22) and 228 (66%) of the 348 participants reported condomless sex in the month before baseline. 24 (14%) of the 173 participants assigned to receive daily SMS reminders later opted for as-needed reminders. 69 291 (97%) of 71 791 SMS reminders were sent as planned. Among participants collecting PrEP (thus potentially suggesting a desire for HIV protection), electronically monitored adherence averaged 26·8% over 24 months and was similar by study group (27·0% with SMS, 26·6% without SMS, adjusted incidence rate ratio 1·16 [95% CI 0·93-1·45], p=0·19). There were no serious adverse events related to trial participation; five social harms occurred in each study group, primarily related to PrEP use.

Interpretation: SMS reminders were ineffective in promoting PrEP adherence among young Kenyan women. Given the overall low adherence in the trial, additional interventions are needed to support PrEP use in this population.

Funding: US National Institute of Mental Health.

PubMed Disclaimer

Conflict of interest statement

Competing interests

JEH reports personal fees from Merck, outside the submitted work; KN reports personal fees from Gilead Sciences and Merck; PA reports personal fees and grants from Gilead Sciences; and JMB reports personal fees from Gilead Sciences, Janssen, and Merck, outside the submitted work. The other authors declare no competing interests.

Figures

Figure 1.
Figure 1.
Participant flow
Figure 2.
Figure 2.
PrEP adherence by electronic monitoring and pharmacy refill by study arm. Adherence was averaged for participants picking up PrEP at each visit; error bars reflect 95% confidence intervals.
Figure 3.
Figure 3.
Correlation between electronically-monitored adherence and tenofovir-diphosphate levels (fmol/punch). Electronically-monitored values reflect the 30 days prior to collection of the drug level.
See this image and copyright information in PMC

Comment in

References

    1. Ziraba A, Orindi B, Muuo S, Floyd S, Birdthistle IJ, Mumah J, et al. Understanding HIV risks among adolescent girls and young women in informal settlements of Nairobi, Kenya: Lessons for DREAMS. PLoS One 2018; 13:e0197479. - PMC - PubMed
    1. Steinberg L A Social Neuroscience Perspective on Adolescent Risk-Taking. Dev Rev 2008; 28:78–106. - PMC - PubMed
    1. Psaros C, Milford C, Smit JA, Greener L, Mosery N, Matthews LT, et al. HIV Prevention Among Young Women in South Africa: Understanding Multiple Layers of Risk. Arch Sex Behav 2018; 47:1969–82. - PMC - PubMed
    1. Haberer JE. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS 2016; 11:10–7. - PMC - PubMed
    1. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015; 372:509–18. - PMC - PubMed

Publication types

Associated data